BiomX Inc. (NYSEMKT:PHGE) Stake Cut by 8Vc Gp I LLC

8Vc Gp I LLC decreased its position in BiomX Inc. (NYSEMKT:PHGE) by 90.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,621 shares of the company’s stock after selling 977,570 shares during the period. BiomX comprises 0.2% of 8Vc Gp I LLC’s portfolio, making the stock its 3rd largest holding. 8Vc Gp I LLC’s holdings in BiomX were worth $111,000 at the end of the most recent quarter.

Separately, Ikarian Capital LLC acquired a new stake in BiomX in the first quarter valued at $4,868,000. 40.57% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of BiomX in a research report on Friday, August 16th.

BiomX Stock Down 17.3 %

BiomX stock opened at $0.62 on Monday. The firm has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $2.15. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The company has a market capitalization of $11.10 million, a PE ratio of -0.19 and a beta of 1.31.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.